A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial

作者：Xiaobin Shang, Yongjie Xie, Jinpu Yu, Jinpu Yu, Chen Zhang, Gang Zhao, Fei Liang, Liang Liu, Wei‐Hong Zhang, Runmei Li, Wenwen Yu, Jie Yue, Chuangui Chen, Xiaofeng Duan, Zhao Ma, Zuoyu Chen, Yanjuan Xiong, Fan Yang, Jianyu Xiao, Rui Zhang, Pengpeng Liu, Yanan Cheng, Feng Guo, Feng Guo, Guoyan Liu, Bin Meng, Dejun Zhou, Yan Sun, Xiubao Ren, Jun Yu, Jun Yu, Jihui Hao, Hongjing Jiang · 发表于：Cancer Cell · 年份：2024 · DOI：10.1016/j.ccell.2024.09.008 · 被引用次数：53 · 研究领域：Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers、Pancreatic and Hepatic Oncology Research